Cargando…
Guideline-level monitoring, biomarker levels and pharmacological treatment in migrants and native Danes with type 2 diabetes: Population-wide analyses
The prevalence of type 2 diabetes (T2D) is higher in migrants compared to native populations in many countries, but the evidence on disparities in T2D care in migrants is inconsistent. Therefore, this study aimed to examine this in Denmark. In a cross-sectional, register-based study on 254,097 indiv...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584163/ https://www.ncbi.nlm.nih.gov/pubmed/37851595 http://dx.doi.org/10.1371/journal.pgph.0001277 |
_version_ | 1785122694499401728 |
---|---|
author | Isaksen, Anders Aasted Sandbæk, Annelli Skriver, Mette Vinther Andersen, Gregers Stig Bjerg, Lasse |
author_facet | Isaksen, Anders Aasted Sandbæk, Annelli Skriver, Mette Vinther Andersen, Gregers Stig Bjerg, Lasse |
author_sort | Isaksen, Anders Aasted |
collection | PubMed |
description | The prevalence of type 2 diabetes (T2D) is higher in migrants compared to native populations in many countries, but the evidence on disparities in T2D care in migrants is inconsistent. Therefore, this study aimed to examine this in Denmark. In a cross-sectional, register-based study on 254,097 individuals with T2D, 11 indicators of guideline-level care were analysed: a) monitoring: hemoglobin-A1c (HbA1c), low-density lipoprotein cholesterol (LDL-C), screening for diabetic nephropathy, retinopathy, and foot disease, b) biomarker control: HbA1c and LDL-C levels, and c) pharmacological treatment: glucose-lowering drugs (GLD), lipid-lowering drugs, angiotensin-converting enzyme-inhibitors/angiotensin receptor blockers, and antiplatelet therapy. Migrants were grouped by countries of origin: Middle East, Europe, Turkey, Former Yugoslavia, Pakistan, Sri Lanka, Somalia, Vietnam. In all migrant groups except the Europe-group, T2D was more prevalent than in native Danes (crude relative risk (RR) from 0.62 [0.61–0.64] (Europe) to 3.98 [3.82–4.14] (Sri Lanka)). In eight indicators, non-fulfillment was common (>25% among native Danes). Apart from monitoring in the Sri Lanka-group, migrants were at similar or higher risk of non-fulfillment than native Danes across all indicators of monitoring and biomarker control (RR from 0.64 [0.51–0.80] (HbA1c monitoring, Sri Lanka) to 1.78 [1.67–1.90] (LDL-C control, Somalia)), while no overall pattern was observed for pharmacological treatment (RR from 0.61 [0.46–0.80] (GLD, Sri Lanka) to 1.67 [1.34–2.09] (GLD, Somalia)). Care was poorest in migrants from Somalia, who had increased risk in all eleven indicators, and the highest risk in nine. Adjusted risks were elevated in some migrant groups, particularly in indicators of biomarker control (fully-adjusted RR from 0.84 [0.75–0.94] (LDL-C levels, Vietnam) to 1.44 [1.35–1.54] (LDL-C levels, Somalia)). In most migrant groups, T2D was more prevalent, and monitoring and biomarker control was inferior compared to native Danes. Migrants from Somalia received the poorest care overall, and had exceedingly high lipid levels. |
format | Online Article Text |
id | pubmed-10584163 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-105841632023-10-19 Guideline-level monitoring, biomarker levels and pharmacological treatment in migrants and native Danes with type 2 diabetes: Population-wide analyses Isaksen, Anders Aasted Sandbæk, Annelli Skriver, Mette Vinther Andersen, Gregers Stig Bjerg, Lasse PLOS Glob Public Health Research Article The prevalence of type 2 diabetes (T2D) is higher in migrants compared to native populations in many countries, but the evidence on disparities in T2D care in migrants is inconsistent. Therefore, this study aimed to examine this in Denmark. In a cross-sectional, register-based study on 254,097 individuals with T2D, 11 indicators of guideline-level care were analysed: a) monitoring: hemoglobin-A1c (HbA1c), low-density lipoprotein cholesterol (LDL-C), screening for diabetic nephropathy, retinopathy, and foot disease, b) biomarker control: HbA1c and LDL-C levels, and c) pharmacological treatment: glucose-lowering drugs (GLD), lipid-lowering drugs, angiotensin-converting enzyme-inhibitors/angiotensin receptor blockers, and antiplatelet therapy. Migrants were grouped by countries of origin: Middle East, Europe, Turkey, Former Yugoslavia, Pakistan, Sri Lanka, Somalia, Vietnam. In all migrant groups except the Europe-group, T2D was more prevalent than in native Danes (crude relative risk (RR) from 0.62 [0.61–0.64] (Europe) to 3.98 [3.82–4.14] (Sri Lanka)). In eight indicators, non-fulfillment was common (>25% among native Danes). Apart from monitoring in the Sri Lanka-group, migrants were at similar or higher risk of non-fulfillment than native Danes across all indicators of monitoring and biomarker control (RR from 0.64 [0.51–0.80] (HbA1c monitoring, Sri Lanka) to 1.78 [1.67–1.90] (LDL-C control, Somalia)), while no overall pattern was observed for pharmacological treatment (RR from 0.61 [0.46–0.80] (GLD, Sri Lanka) to 1.67 [1.34–2.09] (GLD, Somalia)). Care was poorest in migrants from Somalia, who had increased risk in all eleven indicators, and the highest risk in nine. Adjusted risks were elevated in some migrant groups, particularly in indicators of biomarker control (fully-adjusted RR from 0.84 [0.75–0.94] (LDL-C levels, Vietnam) to 1.44 [1.35–1.54] (LDL-C levels, Somalia)). In most migrant groups, T2D was more prevalent, and monitoring and biomarker control was inferior compared to native Danes. Migrants from Somalia received the poorest care overall, and had exceedingly high lipid levels. Public Library of Science 2023-10-18 /pmc/articles/PMC10584163/ /pubmed/37851595 http://dx.doi.org/10.1371/journal.pgph.0001277 Text en © 2023 Isaksen et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Isaksen, Anders Aasted Sandbæk, Annelli Skriver, Mette Vinther Andersen, Gregers Stig Bjerg, Lasse Guideline-level monitoring, biomarker levels and pharmacological treatment in migrants and native Danes with type 2 diabetes: Population-wide analyses |
title | Guideline-level monitoring, biomarker levels and pharmacological treatment in migrants and native Danes with type 2 diabetes: Population-wide analyses |
title_full | Guideline-level monitoring, biomarker levels and pharmacological treatment in migrants and native Danes with type 2 diabetes: Population-wide analyses |
title_fullStr | Guideline-level monitoring, biomarker levels and pharmacological treatment in migrants and native Danes with type 2 diabetes: Population-wide analyses |
title_full_unstemmed | Guideline-level monitoring, biomarker levels and pharmacological treatment in migrants and native Danes with type 2 diabetes: Population-wide analyses |
title_short | Guideline-level monitoring, biomarker levels and pharmacological treatment in migrants and native Danes with type 2 diabetes: Population-wide analyses |
title_sort | guideline-level monitoring, biomarker levels and pharmacological treatment in migrants and native danes with type 2 diabetes: population-wide analyses |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584163/ https://www.ncbi.nlm.nih.gov/pubmed/37851595 http://dx.doi.org/10.1371/journal.pgph.0001277 |
work_keys_str_mv | AT isaksenandersaasted guidelinelevelmonitoringbiomarkerlevelsandpharmacologicaltreatmentinmigrantsandnativedaneswithtype2diabetespopulationwideanalyses AT sandbækannelli guidelinelevelmonitoringbiomarkerlevelsandpharmacologicaltreatmentinmigrantsandnativedaneswithtype2diabetespopulationwideanalyses AT skrivermettevinther guidelinelevelmonitoringbiomarkerlevelsandpharmacologicaltreatmentinmigrantsandnativedaneswithtype2diabetespopulationwideanalyses AT andersengregersstig guidelinelevelmonitoringbiomarkerlevelsandpharmacologicaltreatmentinmigrantsandnativedaneswithtype2diabetespopulationwideanalyses AT bjerglasse guidelinelevelmonitoringbiomarkerlevelsandpharmacologicaltreatmentinmigrantsandnativedaneswithtype2diabetespopulationwideanalyses |